Potency of immune response in rectal cancer
Rectal cancer is a common cancer that affects more and more young adults.
In recent years, its management has evolved allowing a significant improvement in overall survival.
However, challenges remain...
In a new study published in Clinical Cancer Research,
promising results of IMMUNOSCORE® in LARC may be an effective response to the challenges:
IMMUNOSCORE® identifies LARC patients with a clinical Complete Response who do not relapse
IMMUNOSCORE® identifies patients who have a better survival
>60% additional survival in IMMUNOSCORE® High compared to IMMUNOSCORE® Low
WHAT IS IMMUNOSCORE®
IMMUNOSCORE® is an in vitro diagnostic test measuring the host immune response at the tumor site. It provides a robust, precise, quantitative, and consensus assessment of lymphocytic infiltration and has been shown to predict patient outcome and response to therapies in several indications.
IMMUNOSCORE® has already demonstrated its prognostic performance in early colon cancer in a large international SITC-led study (n= 3,500). This personalized medicine diagnostic test is recommended in the ESMO Clinical Practice Guidelines 2020 for localized colon cancer.
More important than clinico-pathological features, the survival is predetermined by pre-existing immunity.
The Innovation Access Program is a time-limited program with preferential conditions for clinicians wishing to strengthen the patient-centric care.
Through the Innovation Access program, effective immediately:
- Doctors can order IMMUNOSCORE® and receive test results virtually through Veracyte's online portal within 10 working days.
- Program is valid for 1 year and sample size mutually agreed.
ELIGIBILITY- All patients with locally advanced rectal cancer (stages II and III).
- Test performed on diagnostic pinch biopsies (neo-adjuvant treatment- naive patients).
To enroll or find out more about the Innovation Access Program, please fill the form below
1  El Sissy C, et al. A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. Clin Cancer Res. 2020 Oct 1;26(19):5198-5207.